PODDInsulet Corporation

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

James R. Hollingshead

Location

Massachusetts, USA

Exchange

Nasdaq

Website

https://insulet.com

Summary

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes.

Company Info

CEO

James R. Hollingshead

Location

Massachusetts, USA

Exchange

Nasdaq

Website

https://insulet.com

Summary

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes.

AI Insights for PODD
5 min read

Quick Summary

Insulet Corporation is a medical equipment company based in Billerica, Massachusetts, that develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Its core business is built around the Omnipod platform, a wearable, disposable, tubeless insulin pump designed to reduce the burden of multiple daily injections. The company sells primarily through independent distributors and pharmacy channels, which helps it reach patients, clinicians, and payers across diabetes care markets. Its main customers include people with type 1 diabetes, insulin-dependent type 2 diabetes patients, endocrinology practices, diabetes educators, pharmacies, and healthcare systems. Insulet’s value proposition is convenience, automation, and quality-of-life improvement for diabetes patients who need frequent insulin dosing.

Strengths

•

Insulet’s primary strength is its focused leadership in tubeless insulin delivery through the Omnipod platform.

•

The company benefits from a differentiated product design that can be easier and less intrusive for many patients than traditional tubed pumps.

•

Its recurring disposable-pod model supports repeat revenue as long as patient retention remains strong.

•

The supplied financial data show positive operating income, net income, and meaningful gross profit, indicating that the business has scale and profitability.

•

The company also benefits from a strong diabetes-care brand, a growing automated insulin delivery ecosystem, and exposure to long-term growth in connected diabetes management.

Key Risks

•

A major risk is that GLP-1 drugs and other metabolic therapies could reduce insulin needs for some diabetes patients, which may create concerns about long-term device demand.

•

Although type 1 diabetes patients still require insulin, investor sentiment can still be hurt by headlines suggesting reduced demand for diabetes devices.

•

Competition is intensifying from Medtronic, Tandem, Beta Bionics, Sequel Med Tech, and other automated insulin delivery companies.

•

Reimbursement pressure, high patient costs, supply chain issues, regulatory delays, and manufacturing problems could slow adoption or hurt margins.

What to Watch

The supplied dataset is labeled Q3 2026 and lists financial figures for that period, but it also shows the next earnings date as November 5, 2026.
Because of that timing, these figures should be treated as data-provider period figures or preliminary snapshot data rather than independently confirmed reported Q3 earnings unless verified against the company’s formal earnings release.
The Q3 2026 dataset lists operating revenue of $801.7 million, gross profit of $562.6 million, operating income of $129.7 million, net income of $95.0 million, basic EPS of $1.37, and diluted EPS of $1.37.
The same dataset shows selling, general and administrative expense of $344.8 million, research and development expense of $88.1 million, interest expense of $13.5 million, and pre-tax income of $118.7 million.
No dated product launch, partnership, acquisition, or supply-agreement event is confirmed within the provided structured data for the quarter, so those items are not presented here as confirmed quarterly events.

Price Drivers

•

PODD’s stock price is driven heavily by revenue growth, margin progress, earnings, cash flow, and the pace of Omnipod adoption.

•

The company’s valuation metrics show that investors are paying a meaningful premium, with a price-to-earnings ratio of about 28.18, EV-to-revenue of about 3.60, and EV-to-EBITDA of about 17.37.

•

Positive price drivers include strong Omnipod demand, international expansion, higher operating leverage, and continued adoption of automated insulin delivery.

•

Negative price pressure can come from fears that GLP-1 drugs may reduce demand for some diabetes devices, even though many insulin-dependent patients, especially type 1 diabetes patients, still require insulin therapy.

•

Broader market conditions, interest rates, high equity valuations, and competition from Medtronic, Tandem, Beta Bionics, Sequel Med Tech, Abbott, and Dexcom also influence investor sentiment.

Recent News

•

Recent company-related discussion has focused on Insulet’s continued growth in Omnipod adoption, profitability, and the competitive outlook for automated insulin delivery.

•

Investors have also reacted to broader diabetes-treatment news, especially concerns that GLP-1 drugs could reduce demand for some diabetes devices over time.

•

Insulet’s product strategy remains centered on Omnipod, automated insulin delivery, pharmacy access, and connected diabetes-care tools.

•

The provided dataset lists the next earnings date as November 5, 2026, making that update an important upcoming catalyst for confirming financial performance and management commentary.

•

In the absence of dated source details in the supplied data, specific launch or supply-agreement items should be verified against company press releases or SEC filings before being treated as confirmed news.

Market Trends

•

The diabetes technology market is being shaped by growing adoption of continuous glucose monitors, automated insulin delivery, app-based care, and pharmacy reimbursement models.

•

Rising diabetes prevalence and demand for more convenient disease management support long-term interest in wearable insulin delivery systems.

•

This trend supports companies like Insulet because automated insulin delivery systems often depend on CGM data and connected software.

•

At the same time, GLP-1 drugs are changing investor perceptions of diabetes treatment and may create uncertainty about future insulin device demand in some patient groups.

•

Broader market conditions also matter because high equity valuations, interest rate expectations, and macroeconomic risk can affect growth-stock multiples across the medical technology sector.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on PODD

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

No more topics to show